Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Clinical Pharmacology & TherapeuticsVolume 78, Issue 4 p. 412-421 Pharmacodynamics and Drug Action Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Dagmar Kubitza MD, Corresponding Author Dagmar Kubitza MD Bayer HealthCare AG, Wuppertal, GermanyBayer HealthCare AG, Institute of Clinical Pharmacology, D-42096 Wuppertal, Germany. E-mail: [email protected]Search for more papers by this authorMichael Becka PhD, Michael Becka PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorBarbara Voith PhD, Barbara Voith PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorMichael Zuehlsdorf PhD, Michael Zuehlsdorf PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorGeorg Wensing MD, Georg Wensing MD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this author Dagmar Kubitza MD, Corresponding Author Dagmar Kubitza MD Bayer HealthCare AG, Wuppertal, GermanyBayer HealthCare AG, Institute of Clinical Pharmacology, D-42096 Wuppertal, Germany. E-mail: [email protected]Search for more papers by this authorMichael Becka PhD, Michael Becka PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorBarbara Voith PhD, Barbara Voith PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorMichael Zuehlsdorf PhD, Michael Zuehlsdorf PhD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this authorGeorg Wensing MD, Georg Wensing MD Bayer HealthCare AG, Wuppertal, GermanySearch for more papers by this author First published: 05 October 2005 https://doi.org/10.1016/j.clpt.2005.06.011Citations: 87Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Background and Objective There is a clinical need for new oral anticoagulants to prevent and treat thromboembolic diseases. Given its integral role in the coagulation cascade, factor Xa is a particularly promising target for new anticoagulation therapies. The aim of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939, an oral, direct factor Xa inhibitor. Methods This single–center, randomized, single–blinded, placebo–controlled, dose–escalation study included 108 healthy white male subjects aged 19 to 45 years. Subjects received single oral doses of either BAY 59–7939 (1.25–80 mg) or placebo; in addition, 1 group received 2 doses of BAY 59–7939 (5–mg tablet and oral solution) or placebo in a crossover design. Results Oral BAY 59–7939 in single doses up to 80 mg was safe and well tolerated and was not associated with an increased risk of bleeding compared with placebo. Pharmacodynamic effects (inhibition of factor Xa activity, prothrombin time, activated partial thromboplastin time, and HepTest) and plasma concentration profiles were dose–dependent. Maximum inhibition of factor Xa activity was achieved 1 to 4 hours after administration of BAY 59–7939 and ranged from 20% to 61% for the 5– to 80–mg doses. BAY 59–7939 selectively inhibited factor Xa activity; thrombin (factor IIa) and antithrombin were unaffected. Inhibition of factor Xa activity and prolongation of prothrombin time correlated well with BAY 59–7939 plasma concentrations (r = 0.949 and 0.935, respectively). Conclusions BAY 59–7939 was well tolerated with predictable pharmacodynamics and pharmacokinetics across a wide range of doses in healthy male subjects. BAY 59–7939 was shown to be an effective and specific factor Xa inhibitor. Clinical Pharmacology & Therapeutics (2005) 78, 412–421; doi: 10.1016/j.clpt.2005.06.011 Citing Literature Volume78, Issue4October 2005Pages 412-421 RelatedInformation